285 related articles for article (PubMed ID: 10492357)
61. [Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the clinical diagnosis of lung cancer].
Demura Y; Mizuno S; Wakabayashi M; Totani Y; Okamura S; Ameshima S; Ishizaki T; Miyamori I; Ito H; Yonekura Y
Nihon Kokyuki Gakkai Zasshi; 2000 Sep; 38(9):676-81. PubMed ID: 11109804
[TBL] [Abstract][Full Text] [Related]
62. Positron emission tomography in lymphoma: comparison with computed tomography and Gallium-67 single photon emission computed tomography.
Kostakoglu L; Goldsmith SJ
Clin Lymphoma; 2000 Jun; 1(1):67-74; discussion 75-6. PubMed ID: 11707816
[TBL] [Abstract][Full Text] [Related]
63. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET.
Schulte M; Brecht-Krauss D; Heymer B; Guhlmann A; Hartwig E; Sarkar MR; Diederichs CG; Von Baer A; Kotzerke J; Reske SN
J Nucl Med; 2000 Oct; 41(10):1695-701. PubMed ID: 11038000
[TBL] [Abstract][Full Text] [Related]
64. The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma.
Kim HY; Kim JS; Choi DR; Kim HS; Kwon JH; Jang GD; Kim JH; Jung JY; Song HH; Lee YK; Min SK; Hwang HS; Kim HJ; Zang DY; Kim HJ
Cancer Res Treat; 2015 Jul; 47(3):458-64. PubMed ID: 25648095
[TBL] [Abstract][Full Text] [Related]
65. The relation of bone marrow scintigraphy and unilateral bone marrow biopsy in malignant lymphoma.
Esmaili J; Safaee SR; Sharifian R; Shoeybi S; Gholamrezanezhad A
Hell J Nucl Med; 2005; 8(2):125-8. PubMed ID: 16142255
[TBL] [Abstract][Full Text] [Related]
66. Dichotomy between Tc-99m MDP bone scan and fluorine-18 fluorodeoxyglucose coincidence detection positron emission tomography in patients with non-Hodgkin's lymphoma.
Lee J; Park CH; Kim HC; Kim HS
Clin Nucl Med; 2000 Jul; 25(7):532-5. PubMed ID: 10885695
[TBL] [Abstract][Full Text] [Related]
67. Usefulness of FDG PET for diagnosis and radiotherapy of the patient with malignant lymphoma involving bone marrow.
Nihashi T; Hayasaka K; Itou T; Sobajima T; Kato R; Ito K; Ito Y; Ishigaki T; Naganawa S
Radiat Med; 2007 Apr; 25(3):130-4. PubMed ID: 17450338
[TBL] [Abstract][Full Text] [Related]
68. Fluorine-18-fluorodeoxyglucose positron emission tomography metabolic imaging in patients with lymphoma.
Huić D; Dodig D
Croat Med J; 2002 Oct; 43(5):541-5. PubMed ID: 12402392
[TBL] [Abstract][Full Text] [Related]
69. Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma.
Schöder H; Meta J; Yap C; Ariannejad M; Rao J; Phelps ME; Valk PE; Sayre J; Czernin J
J Nucl Med; 2001 Aug; 42(8):1139-43. PubMed ID: 11483671
[TBL] [Abstract][Full Text] [Related]
70. Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children.
Kellenberger CJ; Miller SF; Khan M; Gilday DL; Weitzman S; Babyn PS
Eur Radiol; 2004 Oct; 14(10):1829-41. PubMed ID: 15365752
[TBL] [Abstract][Full Text] [Related]
71. Clinical impact of whole-body FDG-PET for evaluation of response and therapeutic decision-making of primary lymphoma of bone.
Park YH; Kim S; Choi SJ; Ryoo BY; Yang SH; Cheon GJ; Choi CW; Lim SM; Yoo JY; Lee SS
Ann Oncol; 2005 Aug; 16(8):1401-2. PubMed ID: 15870088
[No Abstract] [Full Text] [Related]
72. Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients.
Miller E; Metser U; Avrahami G; Dvir R; Valdman D; Sira LB; Sayar D; Burstein Y; Toren A; Yaniv I; Even-Sapir E
J Comput Assist Tomogr; 2006; 30(4):689-94. PubMed ID: 16845304
[TBL] [Abstract][Full Text] [Related]
73. PET scans in the staging of lymphoma: current status.
Friedberg JW; Chengazi V
Oncologist; 2003; 8(5):438-47. PubMed ID: 14530496
[TBL] [Abstract][Full Text] [Related]
74. Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis.
Guhlmann A; Brecht-Krauss D; Suger G; Glatting G; Kotzerke J; Kinzl L; Reske SN
J Nucl Med; 1998 Dec; 39(12):2145-52. PubMed ID: 9867159
[TBL] [Abstract][Full Text] [Related]
75. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients.
Weiler-Sagie M; Bushelev O; Epelbaum R; Dann EJ; Haim N; Avivi I; Ben-Barak A; Ben-Arie Y; Bar-Shalom R; Israel O
J Nucl Med; 2010 Jan; 51(1):25-30. PubMed ID: 20009002
[TBL] [Abstract][Full Text] [Related]
76. Detection of lymphoma in bone marrow by whole-body positron emission tomography.
Carr R; Barrington SF; Madan B; O'Doherty MJ; Saunders CA; van der Walt J; Timothy AR
Blood; 1998 May; 91(9):3340-6. PubMed ID: 9558391
[TBL] [Abstract][Full Text] [Related]
77. Positron emission tomography in the evaluation of lymphoma.
Israel O; Keidar Z; Bar-Shalom R
Semin Nucl Med; 2004 Jul; 34(3):166-79. PubMed ID: 15202099
[TBL] [Abstract][Full Text] [Related]
78. Imaging: staging and evaluation of lymphoma using nuclear medicine.
Divgi C
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S11-8. PubMed ID: 15786021
[TBL] [Abstract][Full Text] [Related]
79. [18F]fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging.
Liu FY; Chang JT; Wang HM; Liao CT; Kang CJ; Ng SH; Chan SC; Yen TC
J Clin Oncol; 2006 Feb; 24(4):599-604. PubMed ID: 16446332
[TBL] [Abstract][Full Text] [Related]
80. PET and restaging of malignant lymphoma including residual masses and relapse.
Reske SN
Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S89-96. PubMed ID: 12748829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
